Real World Evidence Solutions Market


The global real world evidence solutions market in terms of revenue was estimated to be worth $1.5 billion in 2022 and is poised to reach $2.9 billion by 2027, growing at a CAGR of 15.2% from 2022 to 2027. The new edition of the report includes profiles for Thermo Fisher Scientific Inc. (US), Elevance Health Inc. (US), Cegedim Health Data (France), LabCorp Holdings (US), HealthVerity Inc. (US), and Datavant (US). The industry insights chapters include value chain analysis, Porter’s five forces analysis, technology analysis, patent analysis, key conferences and events in 2022–2023, pricing analysis, and key stakeholders and buying criteria. The growth of this market is primarily driven by the increasing growth in clinical trials and the shift from volume-based to value-based care. Using RWE and RWD can inform better protocol design, thereby reducing the number of costly protocol amendments, and can enable the creation of synthetic control arms to accelerate trial execution and decrease overall costs. Similarly, RWE can accelerate label expansion and decrease the overall cost of the evidence needed for filing.


Please enter your comment!
Please enter your name here